Filtered By:
Cancer: Non-Small Cell Lung Cancer

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 1077 results found since Jan 2013.

The JAK/STAT Pathway in Skeletal Muscle Pathophysiology
Conclusion and Perspectives The IL-6/JAK/STAT signaling cascade plays a dominant role in skeletal muscle pathophysiology. IL-6 autocrine, paracrine, and endocrine functions assign to its downstream effectors pivotal importance in skeletal muscle-wasting-associated diseases and other multiple system diseases where muscle acts in communication with other organs. Targeting the components of the JAK/STAT pathway recently emerged as a strategic approach for the treatment of inflammatory diseases and human cancer. This review highlights the opposite outcomes on muscle biology caused by the amount of local and systemic release ...
Source: Frontiers in Physiology - April 29, 2019 Category: Physiology Source Type: research

DDR1 and MT1-MMP Expression Levels Are Determinant for Triggering BIK-Mediated Apoptosis by 3D Type I Collagen Matrix in Invasive Basal-Like Breast Carcinoma Cells
In conclusion, and in agreement with the other studies (Ford et al., 2007; Koh et al., 2015; Toy et al., 2015; Takai et al., 2018), our data suggest that during the acquisition of mesenchymal features, the level of full-length DDR1 expression should be considered, in addition to the other markers, as an important biomarker in the prognosis of aggressive breast carcinomas. As summarized in Figure 9, the regulation of cell proliferation and apoptosis by the collagen/DDR1 axis involves a differential activation of DDR1 signaling pathway and thus BIK expression. In the case of the basal-like bre...
Source: Frontiers in Pharmacology - May 2, 2019 Category: Drugs & Pharmacology Source Type: research

MicroRNA ‑214 upregulates HIF‑1α and VEGF by targeting ING4 in lung cancer cells.
In conclusion, it was demonstrated that miR‑214 targeted ING4 in lung cancer cells, and upregulated the HIF‑1α cascade, leading to MMP2 and VEGF upregulation. This approach may help to clarify the role of miRNA in non‑small lung cancer and may be a new therapeutic target for non‑small lung cancer. PMID: 31059086 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - May 8, 2019 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

PLCE1 inhibits apoptosis of non-small cell lung cancer via promoting PTEN methylation.
CONCLUSIONS: PLCE1 inhibits cell apoptosis of NSCLC by promoting PTEN methylation. PMID: 31364122 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - August 2, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Abstract DYRK1A is considered a potential cancer therapeutic target, but the role of DYRK1A in NSCLC oncogenesis and treatment requires further investigation. In our study, high DYRK1A expression was observed in tumour samples from patients with lung cancer compared with normal lung tissues, and the high levels of DYRK1A were related to a reduced survival time in patients with lung cancer. Meanwhile, the DYRK1A inhibitor harmine could suppress the proliferation of NSCLC cells compared to that of the control. As DYRK1A suppression might be effective in treating NSCLC, we next explored the possible specific molecula...
Source: J Cell Mol Med - August 26, 2019 Category: Molecular Biology Authors: Li YL, Ding K, Hu X, Wu LW, Zhou DM, Rao MJ, Lin NM, Zhang C Tags: J Cell Mol Med Source Type: research

39PThe regulation of INK4 locus by long non-coding RNAs
ConclusionsLION is involved in the promotion of cancer cells proliferation such as H1299 and HCT116 cells via regulating p15, p16 and other genes related to G2/M phase control.Legal entity responsible for the studyThe authors.FundingJSPS KAKENHI.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Reduction sensitive nanocarriers mPEG-g-γ-PGA/SSBPEI@siRNA for effective targeted delivery of Survivin siRNA against NSCLC
Publication date: Available online 5 May 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Li Chen, Siyuan Wang, Qinying Liu, Zhihong Zhang, Shaofeng Lin, Qiuhong Zheng, Miaomiao Cheng, Yuying Li, Cui Cheng
Source: Colloids and Surfaces B: Biointerfaces - May 5, 2020 Category: Biochemistry Source Type: research

Propofol Affects Non-Small-Cell Lung Cancer Cell Biology By Regulating the miR-21/PTEN/AKT Pathway In Vitro and In Vivo.
CONCLUSIONS: Our study indicated that propofol inhibited A549 cell growth, accelerated apoptosis via the miR-21/PTEN/AKT pathway in vitro, suppressed NSCLC tumor cell growth, and promoted apoptosis in vivo. Our findings provide new implications for propofol in cancer therapy and indicate that propofol is extremely advantageous in surgical treatment. PMID: 32925348 [PubMed - in process]
Source: Anesthesia and Analgesia - September 16, 2020 Category: Anesthesiology Authors: Zheng X, Dong L, Zhao S, Li Q, Liu D, Zhu X, Ge X, Li R, Wang G Tags: Anesth Analg Source Type: research

Deregulation of a Cis-Acting lncRNA in Non-small Cell Lung Cancer May Control HMGA1 Expression
ConclusionOur results suggest that HMGA1-lnc is a novel cis-acting lncRNA that negatively regulates HMGA1 gene expression in lung cells. Further characterization of this regulatory mechanism may advance our understanding of the maintenance of lung cancer phenotypes and uncover a novel therapeutic intervention point for tumors driven by HMGA1.
Source: Frontiers in Genetics - January 11, 2021 Category: Genetics & Stem Cells Source Type: research

Cancers, Vol. 13, Pages 830: COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target
rek J. Richard Lung cancer has the highest incidence and mortality among all cancers, with non-small cell lung cancer (NSCLC) accounting for 85–90% of all lung cancers. Here we investigated the function of COMMD1 in the repair of DNA double strand breaks (DSBs) and as a prognostic and therapeutic target in NSCLC. COMMD1 function in DSB repair was investigated using reporter assays in COMMD1-siRNA-depleted cells. The role of COMMD1 in NSCLC was investigated using bioinformatic analysis, qRT-PCR and immunoblotting of control and NSCLC cells, tissue microarrays, cell viability and cell cycle experiments. DNA repair assa...
Source: Cancers - February 16, 2021 Category: Cancer & Oncology Authors: Amila Suraweera Pascal H.G. Duijf Christian Jekimovs Karsten Schrobback Cheng Liu Mark N. Adams Kenneth J. O ’Byrne Derek J. Richard Tags: Article Source Type: research

EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in non ‑small cell lung cancer cells
Oncol Rep. 2021 Jun;45(6):102. doi: 10.3892/or.2021.8053. Epub 2021 Apr 28.ABSTRACTOverexpression of ETS‑homologous factor (EHF) in non‑small cell lung cancer (NSCLC) is associated with poor patient prognosis. To explore the mechanism of the effect of EHF in NSCLC, EHF expression was examined in NSCLC and its role in cell proliferation, invasion, cell cycle, and apoptosis of NSCLC cells was evaluated by overexpressing EHF and/or knocking down EHF expression in NSCLC cells in vitro and in cancer cell grafted mice in vivo. The results revealed that the knockdown of EHF expression in NSCLC with siRNA significantly inhibit...
Source: Oncology Reports - April 28, 2021 Category: Cancer & Oncology Authors: Lei Gao Tian Yang Shuo Zhang Yiqian Liang Puyu Shi Hui Ren Peng Hou Mingwei Chen Source Type: research